Sep. 17 at 1:15 PM
Noble Capital Markets Research Report: Cadrenal Therapeutics (
$CVKD) – Acquisition Builds The Pipeline With Anticoagulants In Development
Cadrenal Acquires Complimentary Cardiovascular Products. Cadrenal announced that it has acquired the anti-coagulant assets of eXlthera Pharmaceuticals. The products include frunexian, a Pre-Phase-2 anti-coagulant drug that inhibits a different step in the coagulation cascade from tecarfarin. Frunexian is in development for different indications and could extend Cadrenal’s product line to additional indications that are not served by current drugs. The acquisition also includes an oral formulation and other research-stage molecules.
Read more: https://www.channelchek.com/news-channel/cadrenal-therapeutics-cvkd-acquisition-builds-the-pipeline-with-anticoagulants-in-development
